Hepatology News

Patients who underwent liver transplantation vs. alternative therapy for unresectable colorectal liver metastasis had higher progression-free and overall survival, as well as lower rates of recurrence, researchers reported in JAMA Surgery.

Pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, lowered liver fat content, markers of inflammation and body weight in patients with metabolic dysfunction-associated steatotic liver disease and obesity, research showed.

Healio Gastroenterology is excited to announce the nominees for its annual Disruptive Innovators Awards in gastroenterology and hepatology.

The Federal Trade Commission proposal to ban noncompete clauses for all workers has sent powerful ripples through the health care industry, prompting physicians of all specialties to reevaluate their career trajectories.

A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.

Transgender adults had “more than double” the prevalence of cirrhosis vs. cisgender adults, as well as higher rates of comorbidities linked to liver disease progression, researchers reported in The American Journal of Gastroenterology.

Up to 13% of patients with dementia have lab values that suggest undiagnosed cirrhosis and possible hepatic encephalopathy, an “easily treatable” cause of cognitive impairment, according to a study in The American Journal of Medicine.

Every year on July 28th, clinicians and researchers recognize World Hepatitis Day to bring awareness to one of the world’s deadliest but preventable viruses and continue efforts to meet the global goal of eliminating viral hepatitis by 2030

The FDA has updated the label indication for Livmarli for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, expanding the patient population to include infants aged 12 months and older.

Remaining current on screening for hepatocellular carcinoma correlated with a “survival benefit” in older adults with hepatitis C virus-related cirrhosis who achieved viral cure but later developed HCC, according to researchers.